CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia and is distinctly low in KMT2A-rearranged cases

Cytometry B Clin Cytom. 2021 Mar;100(2):243-248. doi: 10.1002/cyto.b.21865. Epub 2020 Jan 2.

Abstract

Background: CD49f (integrin α6) is a useful marker for minimal residual disease (MRD) detection in B lymphoblastic leukemia and has recently been suggested to mediate infiltration of the central nervous system by leukemic B lymphoblasts. However, data regarding expression of CD49f protein in B lymphoblastic leukemia are limited, and whether CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia is unknown.

Methods: CD49f protein expression was characterized by flow cytometry in a series of 40 cases of B lymphoblastic leukemia, which included the genetic subgroups: KMT2A-rerranged, BCR-ABL1+, ETV6-RUNX1+, hypodiploidy, and hyperdiploidy.

Results: Expression of CD49f differed significantly among the five genetic subgroups studied, whether assessed by percentage of blasts positive for the antigen (p = .0001, Kruskal-Wallis) or median fluorescence intensity (MFI) (p = .0001, Kruskal-Wallis). Moreover, the percentage of CD49f+ blasts and MFI of CD49f were significantly lower in KMT2A-rearranged cases than in cases without KMT2A rearrangement (p = .0002 for both, Mann-Whitney).

Conclusions: CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia, and is distinctly low in KMT2A-rearranged cases.

Keywords: CD49f; KMT2A; flow cytometry; lymphoblastic leukemia.

MeSH terms

  • Histone-Lysine N-Methyltransferase / genetics*
  • Humans
  • Integrin alpha6 / genetics*
  • Myeloid-Lymphoid Leukemia Protein / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*

Substances

  • Integrin alpha6
  • KMT2A protein, human
  • Myeloid-Lymphoid Leukemia Protein
  • Histone-Lysine N-Methyltransferase